NCT07410819 Investigation of the Effectiveness of Cervicothoracic Exercises in Individuals With Carpal Tunnel Syndrome
| NCT ID | NCT07410819 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Medipol University |
| Condition | Carpal Tunnel Syndrome (CTS) |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2025-10-01 |
| Primary Completion | 2026-05-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2025-10-01 with a primary completion date of 2026-05-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This randomized, parallel-group controlled clinical trial aims to investigate the effects of adding cervicothoracic exercises to conventional physiotherapy on pain, functional status, grip strength, and range of motion in individuals with carpal tunnel syndrome (CTS). CTS is a common compressive neuropathy of the median nerve, characterized by pain, numbness, tingling, nocturnal symptoms, and reduced hand function. Sixty adults diagnosed with CTS will be randomly allocated into two groups (n=30 each): a conventional physiotherapy group and a cervicothoracic exercise plus conventional physiotherapy group. The conventional physiotherapy program includes transcutaneous electrical nerve stimulation (TENS), therapeutic ultrasound, median nerve mobilization, wrist range-of-motion exercises, and strengthening exercises. The intervention group will receive the same conventional physiotherapy program in addition to cervicothoracic exercises targeting cervical mobility, scapular stabilization, and thoracic spine mobility. The intervention will be applied five days per week for six weeks. Outcome measures will be assessed at baseline and at the end of week 6. Primary outcomes include pain intensity measured by the Visual Analog Scale (VAS), functional status assessed using the Boston Carpal Tunnel Questionnaire (BCTQ), and grip strength measured with a Jamar hand dynamometer. Secondary outcomes include upper extremity function evaluated using the Disabilities of the Arm, Shoulder and Hand (DASH) questionnaire and wrist and finger range of motion measured with a goniometer. Data will be analyzed using appropriate statistical methods, with statistical significance set at p\<0.05. This study aims to determine whether adding cervicothoracic exercises to conventional physiotherapy provides additional clinical benefits in CTS rehabilitation.
Eligibility Criteria
Inclusion Criteria: * Age over 18 * Symptom duration of at least 12 weeks, * Information about carpal tunnel syndrome received from a physician, * Positive Tinel or Phalen test in carpal compression test, * Pain intensity, Visual Analog Scale, at least 40 mm out of 100 mm Exclusion Criteria: * Any sensory or motor deficit in the ulnar or radial nerve * History of previous surgery or injection in the wrist * Trauma to the neck, shoulder, or upper extremity * Pregnancy * Concurrent cervical radiculopathy or polyneuropathy
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07410819 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Carpal Tunnel Syndrome (CTS). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07410819 currently recruiting?
Yes, NCT07410819 is actively recruiting participants. Contact the research team at zehrakayax@icloud.com for enrollment information.
Where is the NCT07410819 trial being conducted?
This trial is being conducted at Istanbul, Turkey (Türkiye), Istanbul, Turkey (Türkiye).
Who is sponsoring the NCT07410819 clinical trial?
NCT07410819 is sponsored by Medipol University. The trial plans to enroll 60 participants.